rhNGF for Stage 1 Neurotrophic Keratopathy

rhNGF for Stage 1 Neurotrophic Keratopathy

Up next

Goniotomy Outcomes in the IRIS Registry

Dr. Emily Schehlein interviews Dr. Julia H. Joo and Dr. Ang Li on their study which used the IRIS® Registry to investigate the predictive factors for goniotomy success. From their Ophthalmology Glaucoma article, "Factors Associated with Goniotomy Outcomes in the United States." F ...  Show more

A New Visual Field for Hydroxychloroquine Screening

Dr. Rajesh Rao interviews Dr. Michael Marmor on his recent Ophthalmology Retina editorial, A New Visual Field for Hydroxychloroquine Screening, and discuss the performance of the Humphrey 24-2C visual field test for detecting parafoveal and pericentral hydroxychloroquine retinopa ...  Show more

Recommended Episodes

#192 Debate on First-Line Medications for Diabetes
Core IM | Internal Medicine Podcast

SGLT-2i vs. GLP-1? vs Metformin? How do you balance the cost and coverage of first-line options like metformin, SGLT-2, and GLP-1s? How do you choose between SGLT-2 and GLP-1s for comorbidities like CAD or CKD? And how do you weigh their side effects and practical use?🔹 Sponsor: ...  Show more

S3 Episode 2: Treating Type 2 Diabetes in an Aging Population: Geriatric Syndromes, Comorbidities, and Treatment De-escalation
Medscape InDiscussion: Type 2 Diabetes

Drs Carol H. Wysham and Medha Munshi discuss type 2 diabetes in older adults, understanding geriatric syndromes and how they impact care, and when to de-escalate treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarti ...  Show more

#337 - Insulin resistance masterclass: The full body impact of metabolic dysfunction and prevention, diagnosis, and treatment | Ralph DeFronzo, M.D.
The Peter Attia Drive

View the Show Notes Page for This Episode

<a href= "https://peterattiamd.com/subscribe/ ...

  Show more

Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes
Annals On Call Podcast

Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.